Trial record 12 of 495 for:    "tetrasomy 18p" OR "Chromosomal Disorder"

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by Natera, Inc.
Sponsor:
Information provided by (Responsible Party):
Natera, Inc.
ClinicalTrials.gov Identifier:
NCT01852708
First received: May 6, 2013
Last updated: August 29, 2013
Last verified: August 2013
  Purpose

The purpose of this study is to collect maternal blood samples from pregnant women carrying a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.


Condition
Trisomy 21
Trisomy 18
Trisomy 13
Sex Chromosome Abnormalities
Microdeletion Syndromes

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood

Resource links provided by NLM:


Further study details as provided by Natera, Inc.:

Primary Outcome Measures:
  • Sensitivity and Specificity of the test to diagnose microdeletions (eg. 22q and 5p-) and aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: November 2012
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Pregnant Women

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Pregnant women

Criteria

Inclusion Criteria:

  • Age 18 or older at enrollment
  • Singleton pregnancy
  • Fetus with confirmed diagnosis of chromosomal abnormality or genetic disorder through karyotype, FISH or positive microarray results after amniocentesis or chorionic villus testing
  • The biological father of the fetus at least 18 years of age
  • Able to provide informed consent

Exclusion Criteria:

  • Women carrying multiples
  • Pregnancy is a result of IVF with pre-implantation genetic diagnosis
  • Surrogate/egg or sperm donor used
  • Previous participation in this study during a previous pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01852708

Contacts
Contact: Melissa Savage 650-249-9090 ext x411 research@natera.com

Locations
United States, California
Natera, Inc. Recruiting
San Carlos, California, United States, 94070
Principal Investigator: Zachary Demko, PhD         
Sponsors and Collaborators
Natera, Inc.
  More Information

No publications provided

Responsible Party: Natera, Inc.
ClinicalTrials.gov Identifier: NCT01852708     History of Changes
Other Study ID Numbers: 12-014-NPT
Study First Received: May 6, 2013
Last Updated: August 29, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Chromosome Aberrations
Chromosome Disorders
Sex Chromosome Aberrations
Congenital Abnormalities
Down Syndrome
Trisomy
Pathologic Processes
Genetic Diseases, Inborn
Mental Retardation
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Aneuploidy
Chromosome Duplication

ClinicalTrials.gov processed this record on July 20, 2014